68
Participants
Start Date
December 21, 2017
Primary Completion Date
January 1, 2021
Study Completion Date
January 1, 2021
Pegzilarginase
Administered IV
Pembrolizumab
Administered IV
UPMC Cancer Center, Pittsburgh
Oncology & Hematology Associates of SW Virginia, Blacksburg
Charleston Hematology Oncology Associates, Charleston
Emory University, Atlanta
Woodlands Medical Specialists, PA, Pensacola
Mid Florida Hematology and Oncology Centers, Orange City
Moffitt Cancer Center, Tampa
University of Alabama, Mitchell Cancer Institute, Mobile
Sarah Cannon Research Institute, Nashville
West Clinic, Germantown
Oncology Hematology Care Inc., Cincinnati
University of Michigan, Ann Arbor
Karmanos Cancer Institute, Detroit
Washington University, St Louis
Nebraska Cancer Specialists, Omaha
Texas Oncology-Tyler, Tyler
Texas Oncology-Memorial City, Houston
University of Colorado, Aurora
Rocky Mountain Cancer Centers, Denver
Providence Cancer Center, Portland
The Valley Hospital, Luckow Pavilion, Paramus
Fundacion De Investigacion, Hematology/Oncology, San Juan
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Aeglea Biotherapeutics
INDUSTRY